OTCMKTS:IPCIF Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Intellipharmaceutics International Stock (OTCMKTS:IPCIF) Get IPCIF alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume12,042 shsMarket Capitalization$4.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Intellipharmaceutics International Inc. was a Canadian specialty pharmaceutical company focused on developing oral drug-delivery technologies and pharmaceutical products. The company’s research centered on controlled-release, extended-release and targeted-release formulations intended to improve dosing convenience, therapeutic performance and medication safety. Its development portfolio included generic and proprietary medicines, with an emphasis on central nervous system treatments and products designed to address unmet medical needs. Historical pipeline programs included abuse-deterrent opioid formulations such as Rexista and SequestOx, as well as other extended-release pharmaceutical products. Intellipharmaceutics pursued regulatory approvals in the United States and Canada and sought licensing and commercialization arrangements for its products. Founded in 1998 and based in Toronto, Ontario, Intellipharmaceutics operated primarily as a research and development pharmaceutical company rather than a large-scale commercial drug manufacturer. Public records indicate that the company encountered significant financial and operating difficulties in the late 2010s and subsequently discontinued active operations. Current information about its management, commercial activities and product availability is limited.AI Generated. May Contain Errors. Read More Receive IPCIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPCIF Stock News HeadlinesIntellipharmaceutics International Inc. Announces Stock Option GrantFebruary 8, 2024 | finance.yahoo.comIntellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture ExchangeJanuary 2, 2024 | finance.yahoo.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio.September 20 at 1:00 AM | Stansberry Research (Ad)Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2023 ResultsOctober 16, 2023 | finanznachrichten.deIntellipharmaceutics Announces Second Quarter 2023 ResultsJuly 14, 2023 | finance.yahoo.comClosing Bell: Intellipharmaceutics International Inc up on Monday (IPCI)June 27, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Friday (IPCI)June 10, 2023 | theglobeandmail.comIntellipharmaceutics International reports FY 2022 and Q1 2023 resultsJune 6, 2023 | msn.comSee More Headlines IPCIF Stock Analysis - Frequently Asked Questions How were Intellipharmaceutics International's earnings last quarter? Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) posted its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.70). The business earned $0.58 million during the quarter, compared to the consensus estimate of $0.90 million. When did Intellipharmaceutics International's stock split? Shares of Intellipharmaceutics International reverse split before market open on Friday, September 14th 2018.The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Intellipharmaceutics International? Shares of IPCIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/16/2018Today9/20/2026Fiscal Year End11/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:IPCIF CIK1474835 Webwww.intellipharmaceutics.com Phone416-798-3001Fax416-798-3007Employees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$660 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.32) per share Price / BookN/AMiscellaneous Outstanding Shares33,093,000Free Float32,511,000Market Cap$4.96 million OptionableNot Optionable Beta1.53 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:IPCIF) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellipharmaceutics International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellipharmaceutics International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPCIF Stock Alerts